GARY HORBAR: Open Payments
NPI 1851442198 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 34 payments from 11 companies in 2025. Trend: 2023 $845 · 2024 $792 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $213 |
| Novo Nordisk Inc | 7 | $180 |
| GlaxoSmithKline, LLC. | 3 | $80 |
| Exact Sciences Corporation | 3 | $78 |
| SANOFI-AVENTIS U.S. LLC | 2 | $41 |
| Almatica Pharma LLC | 2 | $36 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $24 |
| PFIZER INC. | 1 | $24 |
| Bavarian Nordic A/S | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
Products named: UBRELVY, Ozempic, TRELEGY ELLIPTA, Cologuard Collection Kit, QULIPTA, TZIELD, LOREEV XR, Quviviq.
Industry payments across NY — which companies pay providers there.
